Abstract:The first approved RNAi therapeutics, ONPATTRO, in 2017 moves the concept of RNA interference (RNAi) therapy from research to clinical reality, raising the hopes for the treatment of currently incurable diseases. However, RNAi therapeutics are still facing two main challenges—susceptibility to enzymatic degradation and low ability to escape from endo/lysosome into the cytoplasm. Therefore, we developed disulfide-based nanospheres (DBNPs) as universal vehicles to achieve efficient RNA delivery to address these problems. Notably, the DBNPs possess unique and desirable features, including improved resistance to nuclease degradation, direct cytoplasmic delivery through thiol-mediated cellular uptake, and cytosolic environment-responsive release, greatly enhancing the bioavailability of RNA therapeutics. Additionally, DBNPs are superior in terms of overcoming formidable physiological barriers, including vascular barriers and impermeable tumor tissues. Owning to these advantages, the DBNPs exhibit efficient gene silencing effect when delivering either small interfering RNA (siRNA) or microRNA in various cell lines and generate remarkable growth inhibition in the zebrafish and mouse model of pancreatic tumors as compared to traditional delivery vectors, such as PEI. Therefore, DBNPs have potential application prospect in RNAi therapy both in vitro and in vivo . Statement of Significance RNA interference (RNAi) therapeutics could target and alter any disease-related mRNA translation, thus have great potential in clinical application. Delivery efficiency of RNA modalities into cell cytoplasm is the main problem that currently limit RNAi therapeutics to release their full potential. Most of the known delivery materials suffer from the endo/lysosomal entrapment and enzymatic degradation during endocytosis-dependent uptake, resulting unsatisfied efficiency of the cytoplasmic release. Here, we developed disulfide-based nanospheres could directly transfer RNA modalities into the cytoplasm and significantly enhance the delivery efficiency, thus holding great potential in RNAi therapy.

Switching the intracellular pathway and enhancing the therapeutic efficacy of small interfering RNA by auroliposome

Efficient Systemic Delivery Of Sirna By Using High-Density Lipoprotein-Mimicking Peptide Lipid Nanoparticles

In vivo self-assembled small RNAs as a new generation of RNAi therapeutics

Direct cytoplasmic delivery of RNAi therapeutics through a non-lysosomal pathway for enhanced gene therapy

Efficient Cytosolic Delivery Of Sirna Using Hdl-Mimicking Nanoparticles

Porous Silicon Microparticles for Delivery of Sirna Therapeutics

Biodistribution of Therapeutic Small Interfering RNAs Delivered with Lipid-Substituted Polyethylenimine-Based Delivery Systems

Lipid-Modified Aminoglycoside Derivatives for in Vivo Sirna Delivery

Liquid crystalline inverted lipid phases encapsulating siRNA enhance lipid nanoparticle mediated transfection

PEGylation of 6-amino-6-deoxy-curdlan for efficient in vivo siRNA delivery

Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms

A Small Molecule Enhances RNA Interference and Promotes Microrna Processing

Metal-organic Frameworks Nanoswitch: Toward Photo-Controllable Endo/lysosomal Rupture and Release for Enhanced Cancer RNA Interference

Small interfering RNA for experimental cancer therapy.

LDLR-Mediated Targeting and Productive Uptake of siRNA-Peptide Ligand Conjugates In Vitro and In Vivo

Biodegradable Stearylated Peptide with Internal Disulfide Bonds for Efficient Delivery of Sirna in Vitro and in Vivo.

Tailoring nanostructured solid-lipid carriers for time-controlled intracellular siRNA kinetics to sustain RNAi-mediated chemosensitization

Recent Advances in Engineering Carriers for siRNA Delivery

Delivery Pathway Regulation of 3′,3″-Bis-peptide-sirna Conjugate Via Nanocarrier Architecture Engineering

Engineering siRNA therapeutics: challenges and strategies

Optimizing long-term stability of siRNA using thermoassemble ionizable reverse pluronic-Bcl2 micelleplexes